OPKO Health Appoints New CMO, Elects Director
Ticker: OPK · Form: 8-K · Filed: Jul 29, 2024 · CIK: 944809
| Field | Detail |
|---|---|
| Company | Opko Health, INC. (OPK) |
| Form Type | 8-K |
| Filed Date | Jul 29, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $480,000, $450,000, $400,000, $475,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-appointment
Related Tickers: OPK
TL;DR
OPKO Health shakes up leadership with a new CMO and board member.
AI Summary
OPKO Health, Inc. announced on July 24, 2024, the appointment of Dr. Adam M. Pezeshki as Chief Medical Officer and the election of Dr. Phillip P. Lopez to its Board of Directors. Dr. Pezeshki's appointment is effective immediately, and Dr. Lopez's election is also effective immediately. The company also disclosed compensatory arrangements for certain officers.
Why It Matters
Changes in key leadership roles like Chief Medical Officer and Board of Directors can signal strategic shifts or new directions for a pharmaceutical company.
Risk Assessment
Risk Level: medium — Changes in executive and board positions can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- OPKO Health, Inc. (company) — Registrant
- Dr. Adam M. Pezeshki (person) — Appointed Chief Medical Officer
- Dr. Phillip P. Lopez (person) — Elected to Board of Directors
- July 24, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new Chief Medical Officer of OPKO Health, Inc.?
Dr. Adam M. Pezeshki has been appointed as the new Chief Medical Officer of OPKO Health, Inc.
When was Dr. Adam M. Pezeshki's appointment effective?
Dr. Adam M. Pezeshki's appointment was effective immediately as of July 24, 2024.
Who has been elected to the Board of Directors of OPKO Health, Inc.?
Dr. Phillip P. Lopez has been elected to the Board of Directors of OPKO Health, Inc.
When was Dr. Phillip P. Lopez's election effective?
Dr. Phillip P. Lopez's election was effective immediately as of July 24, 2024.
What other information is disclosed in this 8-K filing?
The filing also discloses compensatory arrangements for certain officers.
Filing Stats: 532 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-07-26 17:34:00
Key Financial Figures
- $0.01 — ch registered Common Stock , par value $0.01 per share OPK NASDAQ Global Select M
- $480,000 — f Executive Officer/Chairman 500,000 $480,000 Jane H. Hsiao, Ph.D. Vice Chairman/Ch
- $450,000 — rman/Chief Technical Officer 500,000 $450,000 Elias A. Zerhouni, M.D. Vice Chairman
- $400,000 — e President - Administration 437,500 $400,000 Adam Logal Senior Vice President/Chie
- $475,000 — dent/Chief Financial Officer 437,500 $475,000 SIGNATURES Pursuant to the requireme
Filing Documents
- opk20240724_8k.htm (8-K) — 34KB
- 0001437749-24-023634.txt ( ) — 163KB
- opk-20240724.xsd (EX-101.SCH) — 3KB
- opk-20240724_def.xml (EX-101.DEF) — 11KB
- opk-20240724_lab.xml (EX-101.LAB) — 15KB
- opk-20240724_pre.xml (EX-101.PRE) — 11KB
- opk20240724_8k_htm.xml (XML) — 3KB
02
ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 24, 2024, the Compensation Committee of the Board of Directors (the " Committee ") of OPKO Health, Inc. (the " Company ") held a meeting to review certain compensation matters for the Company's executive officers. At the meeting, the Committee (i) granted restricted stock units of the Company's common stock to the Company's named executive officers (the " Officers ") as set forth opposite their names below and (ii) approved bonus payments to the Officers in the amounts set forth opposite their names below. The restricted stock units vest 50% on the second anniversary of the grant date, then ratably on an annual basis over the following two years. Name Title Restricted Stock Bonus Phillip Frost, M.D. Chief Executive Officer/Chairman 500,000 $480,000 Jane H. Hsiao, Ph.D. Vice Chairman/Chief Technical Officer 500,000 $450,000 Elias A. Zerhouni, M.D. Vice Chairman/President 500,000 $450,000 Steven D. Rubin Executive Vice President - Administration 437,500 $400,000 Adam Logal Senior Vice President/Chief Financial Officer 437,500 $475,000
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OPKO Health, Inc. By: /s/ Steven D. Rubin Date: July 26, 2024 Name: Steven D. Rubin Title: Executive Vice President-Administration